Rock Creek Pharmaceuticals Reports on Inhibition of STAT 3 Activation, A Key Marker of Inflammation, In Phase I Clinical Trial in Europe

Rock Creek Pharmaceuticals, Inc., (OTCQB:RCPI) has received an interim report of the pharmacodynamic (PD) results of its Phase I clinical trial of its lead compound, anatabine citrate.
According to the press release:

The Company previously announced that the Phase I trial approved by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA), demonstrated that the drug was safe, well tolerated and had a consistent pharmacokinetic (PK) profile. This PD report highlighted that anatabine citrate produced significant reductions in a key marker of inflammation, STAT 3 (Signal Transducer and Activator of Transcription 3), in human volunteers.

Dr. Michael Mullan, (MBBS, PhD), Chairman and Chief Executive Officer of Rock Creek Pharmaceuticals commented:

These results are very much in concert with what has been previously observed in preclinical and clinical studies of the drug. The fact that STAT 3 activity was significantly, statistically suppressed in the two treated groups, analyzed in depth, is meaningful. Further, this is the first time a drug version of the compound, under strict regulatory conditions, has been shown to be anti-inflammatory in human blood.

Click here to view the full press release.